Walleye Trading
CLDX icon

Walleye Trading’s Celldex Therapeutics CLDX Stock Holding History

Walleye Trading’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,700
Closed -$147K – 4388
2025
Q3 		$147K Buy
+5,700
New +$132K ﹤0.01% 3530
2024
Q1 		– Sell
-4,600
Closed -$182K – 4824
2023
Q4 		$182K Buy
4,600
+3,800
+475% +$112K ﹤0.01% 3836
2023
Q3 		$22K Sell
800
-700
-47% -$21.9K ﹤0.01% 4375
2023
Q2 		$50.9K Buy
+1,500
New +$50.6K ﹤0.01% 3958
2023
Q1 		– Sell
-1,000
Closed -$44.6K – 4891
2022
Q4 		$44.6K Sell
1,000
-2,500
-71% -$89.3K ﹤0.01% 4223
2022
Q3 		$98K Buy
+3,500
New +$107K ﹤0.01% 4058
2022
Q2 		– Sell
-16,100
Closed -$548K – 5177
2022
Q1 		$548K Buy
+16,100
New +$515K ﹤0.01% 2805
2021
Q4 		– Sell
-12,800
Closed -$691K – 5400
2021
Q3 		$691K Buy
+12,800
New +$601K ﹤0.01% 2602

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Walleye Trading's CLDX Position: Q1 2024 in Review

Walleye Trading sold out of Celldex Therapeutics (CLDX) in Q1 2024, closing a stake of 14,079 shares — an estimated $558K sold.

Walleye Trading first reported a position in CLDX in Q4 2015 and held it in 12 quarters. The position peaked at $558K in Q4 2023. 197 funds tracked by Wall St. Rank hold CLDX as of Q1 2024.

  • Walleye Trading reported no remaining Celldex Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Walleye Trading sold 14,079 Celldex Therapeutics shares in Q1 2024, an estimated $558K.
  • Walleye Trading first reported a position in Celldex Therapeutics in Q4 2015 and held it in 12 quarters.
  • Walleye Trading's Celldex Therapeutics position peaked at $558K in Q4 2023.
  • 197 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2024.

Based on Walleye Trading's 13F filing for Q1 2024, filed 15 May 2024.